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Abstract
Sanfilippo syndrome type A or mucopolysaccharidosis IIIA (MPS IIIA) results from the deficiency of the enzyme heparan
N-sulfatase (NS, EC 3.10.1.1), required for the degradation of heparan sulfate. Molecular defects of 24 Italian MPS IIIA
patients were recently reported by our group. We report here two novel mutations: 1040insT and Q365X and the expression
studies on 15 of the identified defects. Transient expression of COS cells by cDNA mutagenized to correspond to heparan N-
sulfatase mutations Y40N, A44T, 166delG, G122R, P128L, L146P, R150Q, D179N, R182C, R206P, P227R, 1040insT,
1093insG, E369K, R377C did not yield active enzyme, demonstrating the deleterious nature of the mutations. Western blot
analysis and metabolic labeling experiments revealed, for cells transfected with wild-type enzyme, a precursor 62-kDa form
and a mature 56-kDa form. Western blot resulted, for 11 mutations, in the presence of both forms, indicating a normal
maturation of the mutant enzyme. Western blot, metabolic labeling and immunofluorescence experiments suggested, for
mutations 166delG, L146P, 1040insT and 1093insG, an increased degradation of the mutant enzymes. ß 2000 Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
The San¢lippo syndrome (mucopolysaccharidosis
III, MPS III) is a lysosomal storage disease due to
impaired degradation of heparan sulfate [1]. MPS III
includes four types, due to the de¢ciency of four
di¡erent enzymes: heparan N-sulfatase (type A);
K-N-acetylglucosaminidase (type B); acetyl CoA:
K-glucosaminide acetyltransferase (type C) and N-
acetylglucosamine 6-sulfatase (type D).
The San¢lippo syndrome is characterized by severe
central nervous system degeneration, but only mild
somatic disease. Onset of clinical features usually oc-
curs between 2 and 6 years, with hyperactivity, ag-
gressive behavior, delayed development, coarse hair,
hirsutism, sleep disorders, hepatosplenomegaly. Se-
vere neurologic degeneration occurs in most patients
by 6^10 years of age, including the characteristic fea-
tures of aphasia, vasomotor instability, seizures, de-
mentia and, eventually, a near-vegetative state.
Death occurs, typically, during the second or third
decade of life. Type A has been reported [2] to be the
most severe, with earlier onset and rapid progression
of symptoms and shorter survival.
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Interest in San¢lippo syndrome type A has re-
sulted in the recent cloning [3] of the cDNA encoding
heparan N-sulfatase (NS, sulfamate sulfohydrolase
or sulfamidase, EC 3.10.1.1). The NS gene has
been mapped to chromosome 17q25.3 and the orga-
nization of the coding sequences has also been deter-
mined: the gene contains eight exons and seven in-
trons, spanning 11 kb [4]. To date, approximately 40
mutations have been described including missense
mutations, deletions of 1, 9 and 11 bp, insertions
of 1 and 18 bp, one nonsense and one splicing muta-
tion [5^8]. Recently we reported the identi¢cation of
16 molecular defects, 13 novel, in a group of 24
Italian patients [9].
Despite an increased e¡ort to identify molecular
defects in the NS gene, no studies have directly in-
vestigated the e¡ect of MPS IIIA mutations through
direct expression of mutated NS. In the present pa-
per, we report the identi¢cation of two novel alter-
ations and the results on transient expression of COS
cells by cDNA mutagenized to correspond to 15 of
heparan N-sulfatase mutations identi¢ed by our
group.
2. Materials and methods
2.1. Patients, DNA extraction, mutation analysis
Patients C.M., G.M., V.C. and C.G. were de-
scribed elsewhere [9]; they showed severe phenotype,
except G.M., who was classi¢ed as intermediate
form. Patients reported in this study: R.M. (inter-
mediate form) P.E., A.F., R.L. (severe forms) were
all from non-consanguineous matings.
Genomic DNA extraction from cultured ¢bro-
blasts, PCR conditions, single-strand conformation
polymorphism (SSCP) procedure, direct sequencing
of fragments with anomalous migration pattern,
were performed as previously described [9] with mi-
nor modi¢cations. In detail, changes concerned the
acrylamide concentration (10% for exons I^III and
8% for exons IV^VIII), percentage of glycerol (0%
and/or 10% for all exons) and the current applied
during SSCP electrophoretic run (6 W for all exons).
To con¢rm the authenticity of the two novel mu-
tations, an aliquot of the PCR products was sub-
jected to restriction enzyme analysis according to
the manufacturer’s instructions (New England Bio-
labs, Beverly, MA): BstXI and BfaI were utilized for
mutations 1040insT and Q365X, respectively. The
digested fragments were electrophoresed in 2% aga-
rose gel.
2.2. Constructs
NS cDNA mutants were generated by site-directed
mutagenesis using the commercially available Trans-
former II kit (Clontech) according to manufacturer’s
instructions. Each mutant was constructed using the
double-stranded vector pcDNA3-ns2 and two oligo-
nucleotides: one mutagenic oligonucleotide contain-
ing the point mutation desired and the Mut-SspI
selection oligonucleotide, which abolish the unique
SspI restriction site in the vector for selection. The
sequences of the oligonucleotides used to introduce
mutations into the wild-type heparan N-sulfatase
cDNA are indicated in Table 1. Mutant constructs
were generated for mutations Y40N, A44T, 166delG,
G122R, P128L, L146P, R150Q, D179N, R182C,
R206P, P227R, 1040insT, 1093insG, E369K,
R377C. Mutant construct for Q365X alteration was
Table 1
Oligonucleotides used for mutagenesis
Oligo-
nucleotide
Sequences
Y40N 5P-TTGAGAGTGGCGCGAACAACAACAGCGCC-3P
A44T 5P-GCGTACAACAACAGCACCATCGCCACCCCGC-3P
166delG 5P-CCCCGCACCTGGAC_CCTTGGCCCGCCGC-3P
G122R 5P-CGCACAGGCATCATCAGGAAGAAGCACGTGG-3P
P128L 5-P-AGAAGCACGTGGGGCTGGAGACCGTGTACCC-3P
L146P 5P-GAATGGCTCCGTCCCCCAGGTGGGGCGGA-3P
R150Q 5P-CCTCCAGGTGGGGCAGAACATCACTAGAA-3P
D179N 5P-TACGTCGCCTTCCACAACCCCCACCGCTGTG-3P
R182C 5P-TTCCACGAGCCCCACTGCTGTGGGCACTCCC-3P
R206P 5P-GAGAGCGGCATGGGTCCTATCCCAGACTGGAC-3P
P227R 5P-TGCCTTACTTCGTCCGCAACACCCCGGCAGC-3P
1040insT 5P-GAAGACCATCCACCTTCACTGGCCGGTCCCTC-3P
1093insG 5P-CCTCTGGGCCACCGGTCTTTGGCAGCCAG-3P
E369K 5P-GCCAGAGCCACCACAAGGTCACCATGTCC-3P
R377C 5P-ATGTCCTACCCCATGTGCTCCGTGCAGCACC-3P
Mut-SspI
(selection
primer)
5P-CTTCCTTTTTCGATATCATTGAAGCATTT-3P
The nucleotide substitutions are underlined. The DNA sequence
of each mutant construct was con¢rmed by sequence analysis.
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not obtained due to the di⁄culty of introducing such
defect into pcDNA3-ns2 vector.
2.3. Transfection procedure and protein extracts
COS cells were cultured in DMEM supplemented
with 10% (v/v) FCS, 100 mg/ml penicillin, 100 mg/ml
streptomycin at 37‡C in a 5% CO2/air atmosphere.
Cells were electroporated with wild-type or mutant
cDNA expression vector pcDNA3-ns2 using a Bio-
Rad Gene Pulser apparatus and seeded in 100 mm2
Petri dishes. The experimental conditions were:
4.2U106 cells in 800 Wl of PBS without calcium
and magnesium, 10 Wg of plasmid DNA and a volt-
age pulse of 1200 V, 25 WF. Cells were harvested 48 h
after transfection, washed twice with 150 mM NaCl,
resuspended in the same bu¡er with 0.2 mM phenyl-
methyl-sulfonyl £uoride (PMSF), 1 WM pepstatin A
and 1 WM leupeptin (all from ICN Biomedicals) and
frozen^thawed six times. All transfections were per-
formed in triplicate; each sample was assayed for
total protein content using the Lowry assay [10].
As control for transfection e⁄ciency, 7 Wg of a con-
struct carrying a L-galactosidase reporter gene under
the control of the pSV strong promoter was co-trans-
fected.
2.4. Heparan N-sulfatase and L-galactosidase activity
measurements
NS assay was performed by incubating 30 Wg of
cellular proteins with the substrate 4-methylumbelli-
feryl-K-D-N-sulfoglucosaminide (MU-K-GlcNS), us-
ing the experimental conditions previously described
[11]. L-Galactosidase activity was measured with a
spectrophotometric assay, using as substrate o-nitro-
phenyl-L-D-galactopyranoside [12].
2.5. Western blot analysis
Thirty micrograms of a total soluble cellular pro-
tein were boiled for 5 min in Laemly bu¡er, electro-
phoresed through 10% SDS-PAGE and electroblot-
ted onto nitrocellulose membranes (Bio-Rad). The
membranes were treated with 5% dry milk in TBS-
T (20 mM Tris-HCl pH 7, 50 mM NaCl, 0.1%
Tween 20) to inhibit non-speci¢c binding. Rabbit
antiserum to recombinant human NS was used at a
1:500 dilution in TBS with 1% dry milk. Visualiza-
tion of antibody binding was carried out with ECL
(Amersham), according to the manufacturer’s in-
structions.
2.6. Pulse-chase experiments
Forty eight hours after transfection, cells in 6-cm
plates were starved for 2 h with 1.5 ml methionine-
cysteine-free medium (DMEM, ICN) supplemented
with 2% FCS, then labeled for 30 min with 450
WCi of 35S-EXPRESS Protein Labeling Mix (NEN
Life Science Products) in the same medium. One
plate of COS cells transfected with wild-type cDNA
was labeled for 24 h and medium was collected and
concentrated to 0.5 ml using Millipore Centricon
Centrifugal Filter Devices, with YM-10 membrane,
by spinning 2 h at 3000 rpm in a Beckman centrifuge
CS-6R. After labeling, cells were chased for various
times in DMEM medium supplemented with 10 Wg/
ml cycloheximide, 0.48 and 0.3 g/l cold cysteine and
methionine respectively. Subsequently, cells were
washed three times with PBS, trypsinized, centri-
fuged 5 min at 1500 rpm in Beckman CS-6R centri-
fuge and lysed. Lysis was on ice for 30 min in 1 ml
lysis bu¡er (10 mM Tris-HCl bu¡er pH 7.4, 150 mM
NaCl, 1 mM EDTA pH 8.0, 1% Triton X-100) con-
taining 0.2 mM PMSF, 1 WM pepstatin A and 1 WM
leupeptin. Cell lysates were clari¢ed by centrifugation
at 13 000 rpm for 5 min in an Eppendorf centrifuge
541 SC and incubated overnight with 2 Wl rabbit
anti-NS antiserum. Immune complexes were precipi-
tated with 50 Wl protein A-Sepharose suspension (1:1
in lysis bu¡er), washed three times with lysis bu¡er
and analyzed by SDS PAGE (Tris-HCl Ready gels,
4^15% linear gradient, Bio-Rad) followed by £uorog-
raphy.
2.7. Indirect immuno£uorescence
Transfected cells were grown 48 h on coverslips,
¢xed with 3.7% formaldehyde in PBS, washed with
0.1 M glycine in PBS and permeabilized with 0.1%
Triton X-100 in PBS. After permeabilization, cells
were incubated for 20 min with an antibody mixture
containing the anti-NS human polyclonal antiserum
and the anti-Lamp1 human monoclonal antiserum
(from Developmental Studies Hybridoma Bank, Uni-
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versity of Iowa) followed by 20 min incubation with
the secondary antibody: tetramethyl-rhodamine-con-
jugated anti-rabbit IgG and £uorescein-conjugated
anti-mouse IgG, respectively. Coverslips were
washed twice with PBS and once with H2O and the
reaction visualized under a £uorescence microscope
(Axioplan, Zeiss).
2.8. Reverse transcriptase-PCR (RT-PCR)
Total RNA was isolated from COS cells after 48 h
transfection using RNeasy Handbook kit (Qiagen).
The RNA reverse transcription and the subsequent
PCR ampli¢cation of cDNA were carried out with
1 Wg of total RNA, using the GeneAmp RNA PCR
kit (Perkin Elmer) according to the manufacturer’s
instructions. The sequence of the sense and antisense
primers used for ampli¢cation of speci¢c cDNA is
5P-GCTGCGCGCTGCTGCTAGTCC-3P and 5P-C-
AAGGCGTCCAGGTGCGGGGTGGCGAAGGC-
3P, respectively.
3. Results
3.1. Mutation analysis
We present here a mutational analysis on Italian
MPS IIIA patients, identifying seven mutations, two
novel (Table 2). As shown in Table 2, for patients
C.M, G.M., V.C. and C.G., where the ¢rst allele was
previously identi¢ed [9], the second mutant allele re-
sulted to be 1040insT, E369K, 1093insG (previously
called V361nt+1 by us) and Q365X, respectively.
Two changes, mutations 1040insT and Q365X were
novel. Subjects R.M., P.E. and A.F. were homozy-
gous for mutations R206P, 1039insC and 1091delC
(previously named by us T360nt-1), respectively (Ta-
ble 2). Of these, mutation R206P was recently re-
ported [8]. For patient R.L., only one mutant allele
was identi¢ed, E369K. As shown in Table 2, several
polymorphisms were also identi¢ed, all already de-
scribed in the literature [5,6,8,9].
The novel mutations were con¢rmed by restriction
enzyme analysis (Fig. 1). 1040insT mutation was
con¢rmed by using BstXI digestion: fragments of
232, 149 and 64 bp were obtained from normal
DNA while fragments of 296, 232, 149 and 64 bp
were obtained from patient DNA, showing that the
subject C.M. is heterozygous for this mutation (Fig.
Table 2
Mutations and polymorphisms in the heparan N-sulfatase gene
Patient Allele 1 Allele 2 Polymorphisma
Mutation E¡ect Mutation E¡ect
C.M. A44Tb non-conservative aa change 1040insTc frameshift and chain termination at
codon 501
ins c(676-37)
G.M. R74Cb substitution of aa identical in
several sulfatases
E369K non-conservative aa change ins c(676-37) R456H
V.C. D179Nb non-conservative aa change 1093insG frameshift and chain termination at
codon 501
R.M. R206P non-conservative aa change R206P non-conservative aa change
C.G. P227Rb non-conservative aa change Q365Xc chain termination at codon 365 ins ct(676-37) c(676-268)t
V226A
P.E. 1040insC frameshift and chain
termination at codon 501
1040insC frameshift and chain termination at
codon 501
ins ct(676-37) c(676-268)t
V226A
A.F. 1091delC frameshift and chain
termination at codon 412
1091delC frameshift and chain termination at
codon 412
ins ct(676-37) c(676-268)t
V226A
R.L. E369K non-conservative aa change not identi¢ed R456H
aFor each intronic polymorphism, ¢rst number in parentheses indicates the ¢rst base of the downstream exon.
bMutations previously reported by us [9].
cNovel mutation.
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Table 3
Heparan N-sulfatase activity of NS mutants transiently transfected in COS cells
Cell type NS activitya (nmol/17 h/mg) L-gal activitya (Wmol/h/mg) Normalized NS activityb
Untransfected 4.5 þ 2.3 15.9 þ 7.6 4.5
Wild-type 45.1 þ 10.5 65.3 þ 5.0 45.1
Y40N 4.2 þ 2.3 68.7 þ 8.5 4.2
A44T 3.1 þ 0.7 72.0 þ 7.5 2.8
166delG 4.4 þ 2.7 68.7 þ 1.3 4.4
G122R 3.9 þ 2.0 67.0 þ 2.5 3.9
P128L 5.3 þ 3.1 56.8 þ 9.8 5.9
L146P 2.6 þ 1.3 59.4 þ 9.4 2.9
R150Q 4.7 þ 2.9 63.7 þ 3.9 4.7
D179N 4.0 þ 2.7 63.3 þ 4.6 4.0
R182C 4.1 þ 2.6 73.2 þ 11.0 3.7
R206P 4.9 þ 2.9 66.6 þ 1.8 4.9
P227R 3.8 þ 2.3 79.9 þ 12.0 3.2
1040insT 4.2 þ 2.5 60.4 þ 8.9 4.7
1093insG 4.1 þ 1.9 73.6 þ 0.8 3.7
E369K 3.3 þ 1.3 77.7 þ 8.8 2.7
R377C 3.2 þ 1.1 55.9 þ 12.4 4.0
aValues are the mean þ standard deviation of three independent experiments.
bBy comparison of the L-galactosidase activity of the mutants with the L-galactosidase activity of the wild-type construct, to correct
for transfection variability.
Fig. 1. Restriction enzyme analysis of novel mutations 1040insT and Q365X. PCR ampli¢ed genomic DNA fragments were digested
with appropriate restriction enzymes and the products were separated as described in Section 2. M is the molecular marker 100 bp-
DNA ladder. Restriction site alterations are shown below each panel. Lane 1, undigested samples; lane 2, normal controls; lane 3, pa-
tient. (a) The T insertion at codon 343 led to 1040insT alteration abolishing an BstXI site. The 445-bp PCR product of the normal
control was digested into three fragments of 232, 149 and 64 bp, while in the heteroallelic patient, C.M., four bands were detected
(i.e. 296, 232, 149 and 64 bp). (b) The C to T transition in the Q365X mutation resulted in the appearance of a BfaI restriction site.
An uncleaved 445-bp PCR product was found for the normal allele, while the presence of three bands (i.e. 445, 275 and 170 bp) indi-
cated a heterozygous genotype in patient C.G.
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1a). Mutation Q365X creates a BfaI restriction site
resulting, in patient C.G., in digested products of 275
and 170 bp, while the wild-type ampli¢cation prod-
uct was not cleaved (Fig. 1b).
3.2. Heparan N-sulfatase activity of NS mutants
Nucleotide changes leading to NS mutations
Y40N, A44T, 166delG (previously named A52nt-1),
G122R, P128L, L146P, R150Q, D179N, R182C,
R206P, P227R, 1040insT, 1039insG (previously
V361nt+1), E369K and R377C ([9]; this paper)
were introduced into the wild-type NS expression
vector by site-directed mutagenesis and transiently
transfected into COS cells by electroporation. As
control, a L-galactosidase cDNA carrying plasmid
was routinely co-transfected. Wild-type expression
resulted in a 7.5^13-fold increase in NS activity and
3^11-fold increase in L-galactosidase activity above
background. NS activity of transfected mutants was
indistinguishable from that of untransfected cells
(Table 3).
3.3. Western blot analysis
The presence of mutant NS protein in transfected
COS cell extracts was determined by Western blot
analysis using an anti-human NS polyclonal antise-
rum. Although no enzyme activity was detected by
the transfected mutant cDNA, the amount of cross-
reacting material, visualized by Western blot, for the
majority of alterations was comparable to that found
in cells expressing the wild-type cDNA (Fig. 2). As
shown in Fig. 2, two bands of 62 and 56 kDa were
identi¢ed, related to the precursor-mature forms of
the enzyme, for wild-type as well as for mutations
Y40N, A44T, G122R, P128L, R150Q, D179N,
R182C, R206P, P227R, E369K and R377C. After
densitometric analysis (Fig. 2, bottom) similar behav-
ior was observed for values corresponding to both
precursor and mature forms. No bands of 62 and
56 kDa were visualized in COS cells transfected
with either 166delG or L146P mutant cDNA, while
the pattern of 1040insT and 1093insG mutants
showed the presence of the mature 56-kDa form
Fig. 2. Western blot analysis of NS wild-type and mutants. Top: total extracts of cells transfected with wild-type or mutant cDNAs
were subjected to SDS-PAGE, followed by Western blotting with anti-NS antiserum. M, molecular-mass standards in kDa. Bottom:
densitometric analysis of the 62-kDa form (solid bars) and 56-kDa form (empty bars). Results obtained in this experiment are similar
to those obtained in two additional experiments of identical design.
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and of additional forms. The appearance of a 30-
kDa band in cells transfected with L146P cDNA
and sometimes in cells transfected with other mutant
cDNAs could be related to a degraded form of either
the precursor and/or mature form of the enzyme.
3.4. Metabolic labeling
Maturation experiments were performed in COS
cells transfected with wild-type NS and with mutant
cDNAs. Two days after transfection the cells were
metabolically labeled for 30 min with 35S-Protein
Labeling Mix. Cells transfected with wild-type NS
were harvested directly after the labeling or after
various chase times; medium surrounding such cells,
known to contain only the precursor form of lysoso-
mal enzymes [1] was harvested after 24 h and con-
centrated as described in Section 2. Radioactivity
incorporated into NS was determined after immuno-
precipitation and separation by SDS-PAGE. A pre-
cursor form of 62 kDa was identi¢ed in medium and
cells, undergoing, through an intermediate 60-kDa
form, to a mature polypeptide of 56 kDa, evident
after a 24-h chase period. No further maturation
occurred after 48-h chase (Fig. 3). In cells expressing
mutant cDNAs containing 166delG and L146P alter-
ations, no bands were visualized. In cells expressing
mutant cDNAs with 1040insT maturation of the en-
zyme occurred, but, as shown by densitometric mea-
surements, approximately 50% of the 35S-NS synthe-
sized during the 30-min labeling period was
recovered after the 24-h chase (Fig. 3). Expression
of mutant cDNA containing 1093insG resulted in
few faint bands of low molecular weight (Fig. 3).
3.5. Indirect immuno£uorescence
Indirect immuno£uorescence revealed, for wild-
type and mutants 1040insT and 1093insG a co-local-
ization of NS with the Lamp1 marker, re£ecting their
localization in lysosomes (Fig. 4). Conversely, for
mutants 166delG and L146P, only the lysosomal
Lamp1 marker was evidentiated, while no NS reac-
tion was visible (Fig. 4), thus con¢rming the results
obtained with Western blot and metabolic labeling.
3.6. Reverse transcriptase-PCR (RT-PCR)
To examine if, for mutants 166delG and L146P, a
transcript was present, RT-PCR experiments were
performed. For this purpose, total RNA from COS
cells transfected with the two mutant cDNAs were
reverse-transcribed using two nucleotides present on
coding cDNA (see Section 2); controls containing
Fig. 3. Metabolic labeling of NS wild-type and mutants. COS cells transfected with wild-type and mutant cDNAs were metabolically
labeled for 30 min as described in Section 2 and harvested after the indicated chase periods. Only one plate of cells transfected with
wild-type cDNA was labeled for 24 h and medium was collected and concentrated as described in Section 2. NS polypeptides were
immunoprecipitated from medium (wild-type) and from cell homogenates (wild-type and mutants), separated by SDS-PAGE and de-
tected by autoradiography. Position of molecular-mass markers is shown on the left. In comparison to the wild-type NS, the four mu-
tants with decreased stability are shown.
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total RNA from wild-type transfected cells and from
untransfected cells were also used. As shown in Fig.
5, a fragment of the expected size (137 bp), represent-
ing the NS mRNA was ampli¢ed in all transfected
cells, implying that the cDNA carrying the 166delG
or L146P mutations undergoes transcription.
4. Discussion
MPS IIIA disease results from heterogeneous mu-
tations [5,7^9] as well as from prevalent mutations.
Among these, R245H was the most prevalent defect
in Australasia, accounting for 18/58 mutant alleles,
52/90 in The Netherlands, 10/52 in the United King-
dom [6] and 17/48 in Germany [7]; mutation R74C is
the most prevalent in Poland (18/32) and is the sec-
ond most frequent in Germany (10/48) [7] ; mutation
1091delC was found in 10/22 alleles in Spain [8].
Results on 24 Italian patients [9] showed the preva-
lence of mutation S66W (16/48 alleles). This paper
extends the molecular analysis to four additional
subjects, bringing the number of total alleles exam-
ined by us to 56. Results reported here show the
genetic heterogeneity characteristic of this disease
(novel mutations) and seem to indicate a slightly
higher frequency (4/56 alleles) in Italian patients for
mutation 1091delC (patient A.F., this paper and pa-
tient M.L., [9]).
Two novel alterations were found in this study,
both not present among 30 normal alleles, suggesting
their involvement in MPS IIIA disease. The ¢rst mu-
tation, the heterozygous T insertion at nucleotide
1040, resulted in a frameshift leading to a stop codon
located on amino acid residue 501, hence causing
production of a protein containing 32% of the se-
quence altered and lacking two amino acids. It
should be noted that two di¡erent insertions
(1039insC and 1040insT) were detected in the same
codon 343 in two di¡erent patients (C.M. and P.E.).
Moreover 1039insC was already found in other se-
vere patients [6] thus suggesting that position 343
could be a mutational ‘hot-spot’ for the NS gene.
The second novel mutation, Q365X, was due to a
heterozygous C to T transition at nucleotide 1105
generating a stop codon at position 365. This alter-
ation reduced the encoded NS protein to 364 amino
acids, lacking the last 138 residues. Both the frame-
shift and the stop codon alterations resulted in severe
changes in protein structure/function and correlate
well with the severe phenotype of the involved pa-
tients (C.M. and C.G.). On the other hand, the mu-
tation on the ¢rst allele (Table 2) also seems to lead
to a non-functional protein. Three of the patients
investigated here were homozygous for a mutation
(patients R.M., P.E., A.F.), although consanguineity
was excluded; however a common ancestor of the
parents can be suspected, at least for some of them
(for instance, patient A.F. was from a Jewish family
whose parents were both from the same town).
Heparan N-sulfatase belongs to the sulfatase pro-
tein family including several O-sulfatases, such as
human galactose 6-sulfatase (Gal6S), iduronate-2-
sulfatase (IDS), N-acetylglucosamine 6-sulfatase
(Glu6S), arylsulfatases A, B, C, D, E, F (ARSA,
ARSB, ARSC, ARSD, ARSE, ARSF) and urkin
Fig. 5. RT-PCR analysis. Total RNA samples were reverse
transcribed as described in Section 2 and the PCR ampli¢ed
products were electrophoresed on a 2% agarose gel. M is the
molecular marker 100-bp DNA ladder.
Fig. 4. Intracellular distribution of NS wild-type and mutants. COS cells expressing wild-type and NS mutant cDNAs were ¢xed, per-
meabilized with 0.1% Triton X-100 and labeled with an antibody mixture containing antiserum against human NS and antiserum
against human Lamp1. Bound antibodies were detected by incubation with a secondary antibody reaction: rhodamine-conjugated
anti-rabbit IgG (left) and £uorescein-conjugated anti-mouse IgG (right).
6
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arylsulfatase whose sequences have been compared
[13,14]. There was a striking sequence homology
(about 30%), especially in the N-terminal region. It
has been suggested that highly homologous regions
are necessary for the maintenance of the common
sulfatases function, while non-homologous regions
are important for transmembrane domains, glycosyl-
ation, internal proteolysis and substrate binding. NS,
even if it is a N-sulfatase, shows up to 24% homology
to this family of proteins conserving, particularly,
two consensus sulfatase sequences. The ¢rst one
C(S)PSRASLLTG includes residues Cys-70 and
Arg-74 involved in the sulfatases catalytic site
[15,16]; the second conserved sequence GVRTGII-
GKK spans amino acids 115^124 [3]. Among our
mutations, only R74C and G122R were predicted
to abolish enzyme function and hence cause MPS
IIIA disease. In fact, R74C concerns position 74,
substituting the Arg residue (basic hydrophobic)
with a smaller Cys residue (neutral hydrophylic), pre-
sumably destroying the structure and function of the
active site; mutation G122R, concerns a conserved
position in the second consensus sequence, leading
possibly to local changes that would impair the sec-
ondary structure of the enzyme. The other mutations
found in MPS IIIA patients are scattered along the
entire length of the protein, but none involve amino
acids forming the catalytic pocket.
To investigate the e¡ects of the mutations on the
activity, biosynthesis and stability of the enzyme we
have generated, by in vitro site directed mutagenesis,
15 mutations in the NS gene, 14 described previously
[9] and one described here. All mutant constructs
directed the synthesis of polypeptides with no en-
zyme activity, indicating that the involved defect is
critical for enzyme function. Since 11 mutant con-
structs (Y40N, A44T, G122R, P128L, R150Q,
D179N, R182C, R206P, P227R, E369K, R377C)
yielded at Western blot NS polypeptides with molec-
ular size and stability similar to that obtained with
wild-type, they probably do not induce dramatic
structural changes in the protein.
In cells transfected with 166delG and L146P mu-
tant cDNAs, no protein forms could be detected at
Western blot, metabolic labeling and immuno£uo-
rescence. Reverse transcriptase experiments showed
that RNA was synthesized, although a reduced syn-
thesis cannot be excluded. Most likely, the absence of
cross-reacting material can be ascribed either to loss
of antibody recognition or to extremely unstable pro-
teins. In fact, the single base deletion 166delG causes
frameshift and premature stop at codon 263, produc-
ing a mutant protein with less than 50% of total
amino acids, lacking the C-terminal region that
may destabilize the remaining polypeptide. For the
conservative exchange L146P, substituting a leucine
to a proline residue, a possible explanation is that the
drastic change of the protein structure could a¡ect
either antibody recognition or protein stability. For
mutations 1040insT and 1093insG, a change in the
last 158 and 140 amino acids, respectively, seems not
to prevent a partial processing of the protein. In fact,
the mature 56-kDa form visible at Western blot was
apparently localized in lysosomes as shown by im-
muno£uorescence. However, for these mutants, a re-
duced stability of the 62-kDa precursor can be hy-
pothesized, from the lack of this form accompanied
by additional low molecular mass bands evidentiated
at Western blot, from the intermediate recovery of
35S-labeled polypeptides after the 24-h chase eviden-
tiated for 1040insT and from the faint, low MW
labeled bands found for 1093insG.
Mutation analysis and expression studies of mu-
tant proteins are important to gain insights into the
molecular pathology of the disease and to establish
genotype^phenotype relationships. Phenotype classi-
¢cation of our 28 Italian MPS IIIA patients was
reported previously [9] or in this article and included
14 severe forms, 10 intermediate, one intermediate-
severe, one mild-intermediate and two unknown.
However, a homogeneous patients’ classi¢cation is
very di⁄cult, due to the fact that di¡erent clinicians
were involved and also due to a real di⁄culty to
discriminate among phenotypes in a disease whose
main feature is mental retardation. Nevertheless, a
good genotype^phenotype relationship occurs for
mutations 166delG, L146P, 1040insT and 1093insG
where the results presented on ‘unstable’ mutant pro-
teins correlate well with the severe phenotypes of the
four involved patients.
In conclusion, we have con¢rmed that 15 of the
mutations identi¢ed in MPS IIIA Italian patients are
very likely to be the cause of the disease. Moreover
we demonstrated that the molecular defects even not
a¡ecting the active site, may have profound e¡ects
on enzyme function.
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